Chiome Bioscience (TSE:4583) Cash And Cash Equivalents : 円2,063.3 Mil (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Cash And Cash Equivalents?

Chiome Bioscience's quarterly cash and cash equivalents declined from Mar. 2024 (円1,325.26 Mil) to Jun. 2024 (円1,103.66 Mil) but then increased from Jun. 2024 (円1,103.66 Mil) to Dec. 2024 (円2,063.28 Mil).

Chiome Bioscience's annual cash and cash equivalents declined from Dec. 2022 (円1,727.27 Mil) to Dec. 2023 (円1,325.55 Mil) but then increased from Dec. 2023 (円1,325.55 Mil) to Dec. 2024 (円2,063.28 Mil).

Chiome Bioscience Cash And Cash Equivalents Historical Data

The historical data trend for Chiome Bioscience's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Cash And Cash Equivalents Chart

Chiome Bioscience Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

2,686.32

1,790.99

1,727.27

1,325.55

2,063.28

Chiome Bioscience Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															1,341.81	1,325.55	1,325.26	1,103.66	2,063.28

Chiome Bioscience Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Chiome Bioscience (TSE:4583) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Chiome Bioscience Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Chiome Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071

Website

http://www.chiome.co.jp

Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience Headlines

No Headlines